Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models
Dr. Alison O’Mahony, Eurofins DiscoverX discusses the use of in vitro models of the human tumor microenvironment (TME) to qualify immuno-oncology candidates, prioritize combination strategies and predict clinical outcomes. She gives an overview on the recent failures of IDO inhibitors in the clinic and the immuno-oncology potential of anti-PD-1 antibodies including pembrolizumab.
Publish Date: March 09, 2018 Views: 354
Publish Date: June 20, 2018 Views: 63